New pill TT-702 for advanced solid tumors
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This trial tests a new pill called TT-702, either alone or with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or slow the growth of tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older.
- You have an advanced solid tumor (like colorectal, lung, pancreatic, breast, or prostate cancer) that has not responded to standard treatments or no standard treatment is available.
- You can take care of yourself (ECOG score 0–1) and are expected to live at least 12 weeks.
- You must be willing to provide blood and tumor tissue samples, and have fresh biopsies if possible.
- Your blood counts and organ function must be within certain ranges before starting.
- You must have had prior immunotherapy (unless in a special early phase group).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called DT-7012, given alone or with another immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if DT-7012 can shrink tumors or slow their growth.
This trial tests a new pill called ASN-3186 for people with advanced solid tumors that haven't responded to standard treatments. The drug may work especially well if your cancer has certain DNA repair problems, like a BRCA mutation.
This trial tests an experimental pill (CVL237) for people with advanced solid tumors that lack a protein called PTEN. The study aims to see if the pill can help control the cancer and shrink tumors.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial studies a new drug called HW071021 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests an experimental pill (FS-207) for people with advanced solid tumors that have a specific genetic marker called MSI-H (high microsatellite instability) or dMMR. If you have already had immunotherapy that didn't work, this drug might help by attacking cancer cells in a new way.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.